Avantor and the Dublin, Ireland-based National Institute of Bioprocessing Research and Training (NIBRT) agreed to work together to tackle downstream bottlenecks in buffer preparation when producing monoclonal antibodies (mAbs). As part of the joint effort, Avantor is providing in-line dilution systems for hands-on experience at NIBRT’s training and research facility dedicated to supporting the global bioprocessing industry.

Avantor’s technology adds to NIBRT’s full complement of bioprocessing capabilities, according to Ger Brophy, PhD, executive vp, biopharma production, Avantor.

“Demand for therapeutic biologics is increasing and this will require increased manufacturing productivity.  At the same time, there is significant pressure on the biopharma industry to reduce overall costs while ensuring that safety and quality are not compromised,” explains Brophy. “This has resulted in initiatives to improve efficiency and increase flexibility in bioprocessing facilities. Buffer management is a key process step which is prime for optimization.”

Buffers are a critical component when producing and purifying mAbs and are extensively used in upstream and downstream production.  Recent activities in upstream optimization have resulted in increasing production yields, which has now placed pressure on downstream purification resources. In addition, demand for multi-product facilities has placed a strain on capacity for traditional buffer preparation.

Buffer management can help advance bioprocessing production by reducing downstream bottlenecks and costs, explains Brophy. “Avantor’s collaboration with NIBRT will provide industry leading buffer management training to help mitigate downstream challenges, which will help new therapies to reach patients faster and more cost effectively,” he says.

Dominic Carolan, NIBRT CEO, stated, “This collaboration further advances our mission of providing a world-class research and training center of excellence,” notes Dominic Carolan, NIBRT CEO. “Technicians and professionals will benefit from access to the latest bioprocessing production knowledge, technology and innovation in buffer management. We are delighted to be working closely with Avantor to support the biopharmaceutical industry.”